多瑞吉联合止痛口服液治疗头颈部恶性肿瘤同期放化疗患者口咽疼痛38例观察

Observation of Oral Pharynx Pain Treated with Durogesic Plus Oral Analgesic Liquid in 38 Head and Neck Malignaut Tumor Patieuts during Concurrent Raio Chemotherapy

目的:观察多瑞吉(芬太尼贴剂)联合止痛口服液治疗头颈部恶性肿瘤患者同期放化疗时出现黏膜反应所致中、重度疼痛的控制作用及治疗不良反应。方法:74例头颈部恶性肿瘤患者在同期放化疗时出现口腔溃疡疼痛及咽喉疼痛程度多为中至重度,分为治疗组38例和对照组36例。治疗组采用多瑞吉+生理盐水100 mL+利多卡因100 mg+地塞米松10 mg(口服),对照组采用生理盐水100 mL+利多卡因100 mg+地塞米松10 mg(口服)。观察用药后72 h内镇痛作用和不良反应。结果:用药后疼痛缓解率:治疗组达84.2%,对照组为61.1%,经χ2检验,止痛作用有显著性差异(P<0.05)。多瑞吉不良反应主要为便秘、皮肤瘙痒、嗜睡及恶心呕吐等,发生率低,均能耐受。结论:多瑞吉联合止痛口服液治疗头颈部恶性肿瘤同期放化疗时出现的口腔、咽喉疼痛,疗效高,不良反应小,使患者能顺利完成治疗。

Objective：To observe the efficacy and adverse reaction of Durogesic （thansdermal fenfanul） plus oral liquid for analgesia in patients with head and neck malignant tumors , who occurred moderate or severe pain from mucosal response during concurrent radiochemotherapy. Methods.74 patients were divided into two groups randomly. Treetment group recrived Durogesic and taked orally NS 100 mL,Lidocaine 100 mg and Dexamethasone 10 mg. Control group taked orally NS 100 mL, Lidocaine 100 mg and Dexamethasone 10 mg alone. The analgesic effects and the side effects in 72 h after medicine were observed. Resuts：The pain remission rates of threatment group and control group wrer 84. 2% and 61. 1% respectively （P 〈 0. 05）. The chief adverse reactions of Durogesic were constipation, itch of skin, drowciness,nausea,vomiting and so on. All of adverse reactions were tolerable. Conclusion： Durogesic plus oral liquid for analgcsia had high curative effect and slight adverse effects in pain of oralcavity and laryngeal pharynx in patients with head and neck malignant tumors during concurrent radiochernotherapy. So that patients could successfully complete concurrent radiochemotherapy.